scholarly journals Short- and long-term influences of calcitonin gene-related peptide on the synthesis of acetylcholinesterase in mammalian myotubes

2001 ◽  
Vol 133 (2) ◽  
pp. 229-236 ◽  
Author(s):  
Valter Luiz Da Costa ◽  
Antonio José Lapa ◽  
Rosely O Godinho
Keyword(s):  
Calcitonin Gene Related Peptide ◽  
Related Peptide ◽  
Calcitonin Gene ◽  
Short And Long Term

Abstract P643: Incidence of Ischemic Stroke Among Migraineurs on Calcitonin Gene-Related Peptide Inhibitors

Stroke ◽  
2021 ◽  
Vol 52 (Suppl_1) ◽  
Author(s):  
Juliana Gomez ◽  
Mark Burish ◽  
Sean I Savitz ◽  
Louise D McCullough ◽  
Cecilia Ganduglia Cazaban
Keyword(s):  
Ischemic Stroke ◽  
Age Groups ◽  
Vascular Risk Factor ◽  
The United States ◽  
Calcitonin Gene Related Peptide ◽  
Related Peptide ◽  
Administrative Dataset ◽  
Calcitonin Gene

Introduction: Migraine is common and often disabling. Recent research has focused on a new class of treatments targeting the pain-signaling molecule calcitonin-gene-related peptide (CGRP). CGRP inhibitors are the first preventive therapies designed specifically for migraine. However, CGRP also induces vasodilation, and plays a role in cerebral blood flow autoregulation. The clinical cerebrovascular effects of long-term blockade of CGRP are not yet known. Methods: We analyzed a retrospective cohort of migraine patients from a large administrative dataset in the United States (OPTUM) that covers patients with commercial insurance and Medicare Advantage, during 2018 and 2019, using ICD-10 codes for all types of migraines. Migraine patients were divided into two groups based on their use of CGRP inhibitors (erenumab, fremanezumab, galcanezumab). We determined the incidence of stroke during 2018 and 2019 among both groups. For the group of migraine patients who used CGRP inhibitors, we focused on the incidence of stroke after these medications were initiated. Results: We identified 646,404 migraine patients; 18, 692 (2.9%) of them had used a CGRP inhibitor. Among the users of CGRP inhibitors, 86% were females, and 58% of patients were in the 41 to 65-year-old range. The average time of follow-up was 197 days after initiation of the medication. A total of 1.3 % of patients who used CGRP inhibitors had an ischemic stroke during the follow-up period versus 2.4% of patients who did not use CGRP inhibitors. The lower rate of stroke in the CGRP antibody group was found in both sexes and all age groups. Conclusions: These preliminary results suggest that CGRP inhibitors are not associated with a higher frequency of stroke in the initial months of use. This could be related to the avoidance of these medications in patients with known cardiovascular risk factors. Further analyses will be completed on vascular risk factor incidence in these populations as well as multiple regression. Prospective, long term studies are needed to confirm these results.

Reappearance of calcitonin gene-related peptide-like immunoreactivity in the dorsal horn in long-term dorsal root transected rat

1992 ◽  
Vol 585 (1-2) ◽  
pp. 400-404 ◽  
Author(s):  
F. Piehl ◽  
U. Arvidsson ◽  
H. Johnson ◽  
Å. Dagerlind ◽  
T. Hökfelt ◽  
...  
Keyword(s):  
Dorsal Horn ◽  
Dorsal Root ◽  
Calcitonin Gene Related Peptide ◽  
Related Peptide ◽  
Calcitonin Gene

CGRP ligand and receptor monoclonal antibodies for migraine prevention: Evidence review and clinical implications

Cephalalgia ◽  
2019 ◽  
Vol 39 (3) ◽  
pp. 445-458 ◽  
Author(s):  
David W Dodick
Keyword(s):  
Monoclonal Antibodies ◽  
Preventive Treatment ◽  
Calcitonin Gene Related Peptide ◽  
Long Term Outcomes ◽  
Open Label ◽  
Peptide Receptor ◽  
Related Peptide ◽  
Calcitonin Gene ◽  
Open Label Extension

Background: Monoclonal antibodies that target calcitonin gene-related peptide or the canonical calcitonin gene-related peptide receptor have emerged as effective and well tolerated for the preventive treatment of migraine. These large molecules appear ideally suited for migraine prevention. They have an extended biological half-life, are administered either monthly or quarterly either by subcutaneous injection or intravenous infusion, require minimal or no dose-titration and have the potential for a rapid onset of effect compared to conventional oral preventive drugs. There is high selectivity and they target an important mediator in the pathogenesis of migraine. Investigation: Phase II and pivotal phase III studies have all yielded positive results with a favorable adverse event profile. No serious treatment-related adverse outcomes have thus far been reported in controlled or long-term open-label extension studies. This tolerability profile promises to improve adherence and, possibly, long-term outcomes. Conclusions: Calcitonin gene-related peptide monoclonal antibodies are effective and well tolerated for the preventive treatment of migraine. They have distinct advantages over currently available oral preventive drugs. While treatment-related serious adverse events have not been observed in open-label extension studies, long-term outcomes and safety will require broad exposure in heterogeneous patient populations in clinical practice. In addition, their safety in women, especially during pregnancy, will require longitudinal surveillance. Given the overlapping mechanism(s), the effectiveness of existing (triptans) and emerging (calcitonin gene-related peptide receptor antagonists) acute therapies in those using a calcitonin gene-related peptide mAb will require further study.

scholarly journals Aorta Remodelling Associated with Calcitonin Gene Related Peptide Concentration in Rats with Arterial Hypertension

2009 ◽  
Vol 78 (4) ◽  
pp. 595-602 ◽  
Author(s):  
Petra Kochová ◽  
Zbyněk Tonar ◽  
Vít M. Matějka ◽  
Jitka Švíglerová ◽  
Milan Štengl ◽  
...  
Keyword(s):  
Renal Failure ◽  
Chronic Renal Failure ◽  
Arterial Hypertension ◽  
Volume Fraction ◽  
Calcitonin Gene Related Peptide ◽  
Tunica Media ◽  
Related Peptide ◽  
Unit Thickness ◽  
Calcitonin Gene

Long-term hypertension in arteries leads to remodelling of the arterial wall. We focused on morphological changes in the wall of the subrenal aorta in rats suffering from arterial hypertension and chronic renal failure induced by 5/6 nephrectomy (NX). We quantified the area of the profile of the arterial lumen, the volume fraction of elastin and smooth muscle cells (SMC) in the tunica media, the thickness of the intima-media, the length density of elastin lamellae, the lamellar unit thickness and the lamellar number. Calcitonin gene related peptide (CGRP) was assayed in extracts of aortic tissue and in plasma. Ten days after the subtotal nephrectomy, the structure of the aorta of NX rats did not differ compared to control animals. Pronounced structural changes were observed ten weeks after 5/6 nephrectomy. The area of the lumen profile, the elastin volume fraction and the elastin lamellar number in the tunica media were all significantly higher (p < 0.001) in NX than in control animals. The SMC volume fraction in the tunica media and the lamellar unit thickness were lower (p < 0.001) in NX than in control animals. The CGRP concentration was significantly higher (p < 0.05) in the aortas and in plasma of NX rats both ten days and ten weeks after operation when compared to sham operated animals. Our study demonstrated intensive remodelling of the aorta over the course of 10 weeks following induction of chronic renal failure. This was associated with a long-term increase in calcitonin gene related pep tide concentrations in the plasma and aorta.

Sign in / Sign up

Export Citation Format

Share Document